Supernus Pharmaceuticals (SUPN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Voting matters and shareholder proposals
Election of two directors, Frederick M. Hudson and Charles W. Newhall, III, for three-year terms is proposed, with board recommendation to vote FOR both nominees.
Advisory (non-binding) vote on executive compensation is included, with board recommendation to vote FOR.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, is proposed, with board recommendation to vote FOR.
Proposal to amend the 2021 Equity Incentive Plan to increase the number of shares available under the plan, with board recommendation to vote FOR.
Board of directors and corporate governance
Board recommends all proposals and nominees, indicating unified governance support for the agenda.
Executive compensation and say-on-pay
Shareholders are asked to approve, on a non-binding basis, the compensation paid to named executive officers.
Latest events from Supernus Pharmaceuticals
- Q1 2026 revenue up 39% to $207.7M, net loss narrows, and CNS portfolio expands.SUPN
Q1 20265 May 2026 - Virtual meeting to vote on directors, pay, auditor, and equity plan; strong governance focus.SUPN
Proxy filing30 Apr 2026 - Record 2025 revenue and strong growth in key products set the stage for robust 2026 outlook.SUPN
Q4 202513 Apr 2026 - Four key products drive strong growth and set up a robust outlook for 2026 and beyond.SUPN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - ONAPGO supply stabilized, portfolio growth strong, and new launches and pipeline progressing.SUPN
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Qelbree and Gocovri drove 24% Q2 revenue growth, prompting higher 2024 guidance.SUPN
Q2 20242 Feb 2026 - Qelbree and pipeline progress drive growth amid legacy product transitions and steady guidance.SUPN
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Strong R&D, pipeline catalysts, and Qelbree growth drive future prospects amid generic headwinds.SUPN
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Qelbree accelerates in a rebounding ADHD market as pivotal pipeline data approaches.SUPN
Annual Novel Mechanisms in Neuropsychiatry Summit 202420 Jan 2026